CN111407754A - Application of carglumic acid in preparing medicine for preventing and treating coronavirus - Google Patents

Application of carglumic acid in preparing medicine for preventing and treating coronavirus Download PDF

Info

Publication number
CN111407754A
CN111407754A CN202010265448.1A CN202010265448A CN111407754A CN 111407754 A CN111407754 A CN 111407754A CN 202010265448 A CN202010265448 A CN 202010265448A CN 111407754 A CN111407754 A CN 111407754A
Authority
CN
China
Prior art keywords
cov
coronavirus
sars
hydrochloride
acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202010265448.1A
Other languages
Chinese (zh)
Inventor
袁曙光
邹荣峰
罗木鹏
陈显翀
崔文强
赵金存
孙静
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Shenzhen Institute of Advanced Technology of CAS
Original Assignee
Shenzhen Institute of Advanced Technology of CAS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shenzhen Institute of Advanced Technology of CAS filed Critical Shenzhen Institute of Advanced Technology of CAS
Priority to CN202010265448.1A priority Critical patent/CN111407754A/en
Publication of CN111407754A publication Critical patent/CN111407754A/en
Priority to PCT/CN2020/129185 priority patent/WO2021203703A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Urology & Nephrology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention discloses an application of carglutamic acid in preparing a medicament for preventing and treating coronavirus, in particular an application of carglutamic acid or pharmaceutically acceptable salt, isotope, stereoisomer, mixture of stereoisomer, tautomer, ester, amide or prodrug thereof in preparing a medicament for preventing and/or treating diseases caused by coronavirus, wherein the coronavirus is novel coronavirus SARS-Cov-2, SARS-CoV, HCoV229E, N L63, OC43, HKU1 and MERS-CoV, the half effective concentration of the coronavirus to the novel coronavirus is 13.92 mu M, the toxicity is low, and the treatment window is good.

Description

Application of carglumic acid in preparing medicine for preventing and treating coronavirus
Technical Field
The invention belongs to the field of antiviral drugs, and particularly relates to an application of carglumic acid in preparation of drugs for preventing and treating coronavirus.
Background
New Coronaviridae (COVID-19) is an infectious disease caused by infecting a human body with a novel coronavirus (SARS-Cov-2), and The symptoms thereof mainly include fever, weakness, dry cough, dyspnea and renal failure [ The L ancet,2020,395(10223): 507-; The L ancet,2020,395(10223):497 506 ]. Coronaviridae (Coronaviridae) belonging to The family Coronaviridae (Coronaviridae) in The systematic classification, Coronaviridae (Corona viruses) belonging to The genus coronaviruses are positive strand single strand RNA viruses with mantle (Envelope), The diameter thereof is about 80-120 nm, The genetic material thereof is The largest of all RNA viruses, and The coronaviruses are generally only infected with human, mouse, pig, cat, dog, vertebrate, coronavirus which was first isolated from chicken in 1937, The glycoprotein particle shape is irregular, The diameter thereof is about 60, 220nm, The glycoprotein has The structure of The above glycoprotein (glycoprotein A-19, glycoprotein A) and glycoprotein (glycoprotein A) which are also included in The glycoprotein types of fowl (glycoprotein).
The gene group sequencing shows that SARS-Cov-2 is a single-chain RNA coronavirus with the diameter of 60-140 nm and 9-12 nm prickle outside the envelope, and is similar to corolla, and the comparison with other virus sample gene sequences shows that SARS-Cov-2 is similar to SARS-CoV (79.5%) [ Nature,2020] and bat coronavirus (96%) [ bioRxiv,2020,2020.01.22.914952 ], and the virus is presumed to possibly originate from bat [ bioRxiv,2020,2020.01.24.915157; Nature,2020 ]. SARS-Cov-2 belongs to β CoV, which is the 7 th member of HCoV family different from SARS-CoV and MERS-CoV [ New England of medicinal, 2020], and the other 6 members include HCoV 36229 54, OC 57, HKU 82, SARS-Cov and MERS-CoV.
The development of effective antiviral drugs and vaccines is the most urgent task at present, the treatment of COVID-19 mainly depends on the adjuvant therapy for the symptoms, but lacks effective specific drugs and vaccines, however, the development of new drugs and vaccine is a time-consuming process, not only has a long development period, but also is a time-consuming project after the approval of the market, the search for "old drugs" having the effect of resisting infection of SARS-Cov-2 virus from the marketed drugs is an effective strategy for treating and preventing the outbreak disease of the COVID-2 virus, the main anti-SARS-Cov-2 virus includes RNA inhibitor, polymerase inhibitor, β interferon, monoclonal antibody, etc., and the analysis of the activity of these drugs and vaccines in vitro is not yet effective50In vivo efficacy is still being observed between low micromolar to medium micromolar.
Card glutamic acid was developed by the company Orphan Europe, approved by European EMA to market 24.1.2003, approved by FDA to market 18.3.2010, approved by Japanese PMDA to market 28.9.2016, and sold by Orphan Europe and Pola Pharma under the trade name of
Figure BDA0002441113420000021
Carbamic acid is a formyl phosphate synthase 1(CPS1) activator, and is used for treating hyperammonemia (also called urea cycle metabolism disease) caused by N-acetylase synthesis disorder, isovaleric acidemia, methylmalonic acidemia and propionic acidemia. In view of the result of virtual drug screening, the application research of carglumic acid in the antiviral effect of the novel coronavirus of the new coronary pneumonia is carried out.
The development of effective specific drugs for treating coronavirus pneumonia is an urgent problem to be solved. In the aspect of developing medicine for treating new type coronavirus (SARS-Cov-2) virus, the invention researches the effect of carglutamic acid on resisting SARS-Cov-2 virus.
Disclosure of Invention
The invention aims to provide application of carglumic acid in preparing a medicament for preventing or treating diseases caused by coronavirus.
Specifically, to solve the technical problem of the present invention, the following technical solutions are adopted:
the invention provides application of carglutamic acid or pharmaceutically acceptable salt, isotope, stereoisomer, mixture of stereoisomer, tautomer, ester, amide or prodrug thereof in preparing a medicament for preventing and/or treating diseases caused by coronavirus.
In the technical scheme of the invention, the coronavirus is novel coronavirus SARS-Cov-2, SARS-CoV, HCoV229E, N L63, OC43, HKU1 and MERS-CoV.
In the technical scheme of the invention, the disease caused by the coronavirus is infectious disease or complication thereof caused by any virus of SARS-Cov-2, SARS-CoV, HCoV229E, N L63, HCoV-OC43, HKU1 or MERS-CoV, and is preferably respiratory tract infection disease, such as severe acute respiratory syndrome, severe acute respiratory syndrome coronavirus type 2 and middle east respiratory syndrome.
In the technical scheme of the invention, the carglumic acid is shown as a structural formula (1)
Figure BDA0002441113420000031
In the technical scheme of the invention, the application of carglumic acid or pharmaceutically acceptable salts, isotopes, stereoisomers, mixtures of stereoisomers, tautomers, esters, amides or prodrugs thereof as a unique active ingredient in preparing medicines for preventing and/or treating diseases caused by coronavirus.
In the technical scheme of the invention, the application of the composition prepared from the carglutamic acid or pharmaceutically acceptable salts, isotopes, stereoisomers, mixture of stereoisomers, tautomers, esters, amides or prodrugs thereof and other antiviral drugs as an active ingredient in preparing drugs for preventing and/or treating diseases caused by coronavirus.
In the technical scheme of the invention, the other antiviral drugs are selected from ganciclovir, acyclovir, amantadine, oseltamivir, abacavir, acemannan, acyclovir sodium, adefovir, alovudine, avsunotol, tricyclodecylamine hydrochloride, alaudine, alitame, adefovir, cidofenac, emtricitabine, cytarabine hydrochloride, delavirdine mesylate, desciclovir, didanosine, dioxaxaline, edexuridine, virin, itracetipine, envilarden, engivir oxime, hopudine, famciclovir hydrochloride, clofenacil, fossilidine, foscarnet sodium, ganciclovir sodium, idoxuridine, indinavir, ethoxybutotid, lamivudine, lomicrivir, locarine, lovir adenosine, lopinavir, Memantine hydrochloride, methylthioninium chloride, nelfinavir, nevirapine, penciclovir, pirodapvir, ribavirin, saquinavir mesylate, ritonavir, sotalomide hydrochloride, solivudine, penicillin, stavudine, tenofovir, trovudine hydrochloride, valacyclovir hydrochloride, vidarabine phosphate, vidarabine sodium phosphate, tipranavir, viroxime, zalcitabine, zidovudine, and neat oxime.
In another aspect, the present invention provides a pharmaceutical composition for treating or preventing diseases caused by viruses of the family Coronaviridae, comprising carvoglutamic acid or a pharmaceutically acceptable salt, isotope, stereoisomer, mixture of stereoisomers, tautomer, ester, amide or prodrug thereof.
In the technical scheme of the invention, the pharmaceutical composition also comprises pharmaceutically acceptable auxiliary materials.
In the technical scheme of the invention, the dosage form of the pharmaceutical composition is oral preparation, lung inhalation preparation, mucosa administration preparation, eye preparation or injection.
In the technical scheme of the invention, the oral preparation is selected from granules, powder, pills, tablets, capsules or oral liquid.
In another aspect, the invention provides the use of carglumic acid as a disinfectant against viruses of the family coronaviridae.
In another aspect of the present invention, there is provided a disinfectant for removing contamination by viruses of the family coronaviridae, the disinfectant comprising carvonine.
Another aspect of the invention provides a method for treating a disease caused by a virus of the family coronaviridae, comprising administering to a subject a therapeutically effective amount of carvonic acid or a pharmaceutically acceptable salt, isotope, stereoisomer, mixture of stereoisomers, tautomer, ester, amide or prodrug thereof.
Another aspect of the invention provides a method for preventing infection of a subject with a virus of the family coronaviridae, comprising administering to the subject a therapeutically effective amount of carvonic acid or a pharmaceutically acceptable salt, isotope, stereoisomer, mixture of stereoisomers, tautomer, ester or prodrug thereof, prior to infection.
Advantageous effects
The invention discloses a medicine using carglumic acid as main component and its application in resisting new coronary pneumonia (COVID-19) new type coronavirus (SARS-Cov-2) infection. The invention discovers for the first time that the carglutamic acid has antiviral effect on the novel coronavirus, can block the novel coronavirus from infecting host cells, and can be used for treating diseases for resisting the novel coronavirus infection of the novel coronavirus.
Half the Effective Concentration (EC) of carglumic acid in African green monkey kidney cell (VeroE6) against novel coronavirus of new coronary pneumonia (SARS-Cov-2)50) 13.92 mu M, low toxicity and good therapeutic window.
Detailed Description
In order to make the aforementioned objects, features and advantages of the present invention more comprehensible, specific embodiments of the present invention are described in detail below, but the present invention is not to be construed as limiting the implementable range of the present invention.
Example 1 viral amplification
VeroE6 Vero cells were transformed into 3 × 105One well, inoculated into a 96-well plate, and placed at 37 ℃ in a minimum Eagle' medium (MEM; Gibco Invitrogen) containing 10% fetal bovine serum (FBS; Gibco Invitrogen) with 5% CO2Culturing until the monolayer grows. Diluting new coronavirus clinical isolate 100 times, inoculating to 96-well plate full of monolayer cells, placing at 37 deg.C and 5% CO2Two days of culture (containing normal control).
After two days, the pathological change degree reaches over 75 percent, the mixture is placed in an ultra-low temperature refrigerator at minus 80 ℃, freeze thawing is carried out repeatedly for one time, virus liquid of cell amplification is collected, centrifugation is carried out for 30 minutes at 3000r/min, precipitates are removed, and the mixture is subpackaged into small tubes to be placed in the ultra-low temperature refrigerator at minus 80 ℃ for long-term storage.
EXAMPLE 2 evaluation of toxicity of Carbamate drug
Dissolving carglumic acid powder in DMSO, diluting with culture solution to 20mg/m L final concentration of 1%, filtering with 0.22 μm filter membrane, storing at 4 deg.C, and storing at 2.5 × 10 per well4Inoculating the cells to a 96-well plate, removing culture solution after the cells grow into a monolayer after 24-48 h, adding medicines with different dilutions 100 mu L/well, adding l00 mu L/well MEM into a normal cell control well, and adding 5% CO at 37 DEG C2Continuously culturing for 2-5 days, adding CCK8 method solution (5mg/m L) 20 μ L per well, and placing at 37 deg.C with 5% CO2And (3) continuously incubating for 4 hours in the incubator, removing culture supernatant, adding 00 mu L dimethyl sulfoxide (DMSO) into each hole, oscillating at a low speed for 10 minutes to fully dissolve crystals, selecting 490nm wavelength, and measuring the light absorption value of each hole on an enzyme-linked immunosorbent assay monitor.
EXAMPLE 3 evaluation of the drug efficacy of Carbamate against the novel coronavirus of New Copyneumoniae
To evaluate the antiviral efficacy of the drugs, VeroE6 cells were grown at a density of 5 × 104Cells/well in 48-well cell culture dishes overnight. AddingThe virus (MOI 0.05) was allowed to infect for 2 hours. Then 2-fold gradient diluted drug was added, 4 multiple wells were set for each concentration, 200 μ M was used as the initial concentration of drug, 5% CO at 34 deg.C2Incubate in incubator for 2 days. Cytopathic Effect (CPE) was recorded, CPE was recorded in the cells according to 6-grade criteria, after CPE was recorded, staining was performed by CCK8 method, OD was measured, and half effective concentration of drug (EC) was calculated by Reed-Muench method50). Half the Effective Concentration (EC) of CAGLUTINE against the novel coronavirus of New crown pneumonia (SARS-Cov-2)50) The concentration was 13.92. mu.M. The results of experiments show that foscarnet sodium has low antiviral half effective concentration and good antiviral effect.
Example 4 immunofluorescence assay
Immunofluorescence microscopy to detect expression of viral proteins in VeroE6 cells, the cells of example 3 were fixed with 4% paraformaldehyde and permeabilized with 0.5% TritonX-100, then the cells were blocked with 5% Bovine Serum Albumin (BSA) for 2 hours at room temperature, the cells were incubated with primary antibody (viral nucleocapsid protein polyclonal antibody of bat SARS-associated coronavirus, anti-NP, at 1: 1000 dilution) for 2 hours, then incubated with secondary antibody (488) incubated antibody (H + L) the nuclei were stained with Hoechst33258 dye (Beyohe, China) observation by fluorescence microscopy revealed that carglutamic acid was effective in killing viruses in the cells and had little effect on the cells, with a good therapeutic window.

Claims (10)

1. Use of carglumic acid or a pharmaceutically acceptable salt, isotope, stereoisomer, mixture of stereoisomers, tautomer, ester, amide or prodrug thereof for the preparation of a medicament for the prophylaxis and/or treatment of diseases caused by coronaviruses.
2. The use of claim 1, wherein the coronavirus is a novel coronavirus, SARS-Cov-2, SARS-CoV, HCoV229E, N L63, OC43, HKU1 and MERS-CoV.
3. The use according to claim 1, wherein the disease caused by coronavirus is infectious disease caused by SARS-Cov-2, SARS-CoV, HCoV229E, N L63, HCoV-OC43, HKU1 or MERS-CoV or its complications, and the infectious disease is preferably respiratory infectious disease.
4. Use according to claim 1 of carvonic acid or a pharmaceutically acceptable salt, isotope, stereoisomer, mixture of stereoisomers, tautomer, ester, amide or prodrug thereof as sole active ingredient for the preparation of a medicament for the prophylaxis and/or treatment of diseases caused by coronaviruses; or
The application of the composition of carglumic acid or pharmaceutically acceptable salts, isotopes, stereoisomers, mixture of stereoisomers, tautomers, esters, amides or prodrugs thereof and other antiviral drugs as an active ingredient in the preparation of drugs for preventing and/or treating diseases caused by coronaviruses;
preferably, the other antiviral drug is selected from the group consisting of ganciclovir, acyclovir, amantadine, rimantadine, oseltamivir, abacavir, acemenan, acyclovir sodium, adefovir, alovudine, avrinol, amantadine hydrochloride, amantadine, aliquodine mesylate, avridine, cidofovir, cidofophylline, emtricitabine, cytarabine hydrochloride, delavirdine mesylate, desciclovir, didanosine, dioxazoline, edexuridine, emivirin, itracitabine, emviraden, enviroxime, hoplatin, famciclovir, cloquine hydrochloride, decitabine, fexitabine, fexiuridine, foscarnet sodium, fosamivir sodium, idovir sodium, idoside, indinavir, ethoxybutovidone aldehyde, lamivudine, lobbucavir, lodenafine hydrochloride, lopinavir, mavir hydrochloride, mavir sodium acetate, trexate, trematodine hydrochloride, tretinomycin hydrochloride, and sodium acetate, Nelfinavir, nevirapine, penciclovir, pirodavir, ribavirin, saquinavir mesylate, ritonavir, hydrochloric acid of sodamide, solivudine, bractenocillin, stavudine, tenofovir, hydrochloric acid of trovudine, valacyclovir hydrochloride, vidarabine, adenosine phosphate, vidarabine sodium phosphate, tipranavir, viroxim, zalcitabine, zidovudine, net oxime.
5. A pharmaceutical composition for treating or preventing a disease caused by a coronavirus, comprising carvoglutamic acid or a pharmaceutically acceptable salt, isotope, stereoisomer, mixture of stereoisomers, tautomer, ester, amide or prodrug thereof.
6. The pharmaceutical composition of claim 5, further comprising a pharmaceutically acceptable excipient.
7. The pharmaceutical composition according to claim 5, wherein the pharmaceutical composition is in the form of an oral preparation, a pulmonary inhalation preparation, a mucosal administration preparation, an ophthalmic preparation or an injection; preferably, the oral preparation is selected from granules, powders, pills, tablets, capsules or oral liquids.
8. A disinfectant for eliminating contamination by viruses of the family coronaviridae, said disinfectant comprising carglumic acid.
9. A method for treating or preventing a disease caused by a virus of the family coronaviridae, comprising administering to a subject a therapeutically effective amount of carvoglutamic acid or a pharmaceutically acceptable salt, isotope, stereoisomer, mixture of stereoisomers, tautomer, ester, amide or prodrug thereof.
10. The pharmaceutical composition of any one of claims 5-7 or the disinfectant of claim 8 or the method of claim 9, wherein the coronavirus is a novel coronavirus, SARS-Cov-2, SARS-Cov, HCoV229E, N L63, OC43, HKU1, and MERS-Cov.
CN202010265448.1A 2020-04-07 2020-04-07 Application of carglumic acid in preparing medicine for preventing and treating coronavirus Pending CN111407754A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
CN202010265448.1A CN111407754A (en) 2020-04-07 2020-04-07 Application of carglumic acid in preparing medicine for preventing and treating coronavirus
PCT/CN2020/129185 WO2021203703A1 (en) 2020-04-07 2020-11-16 Use of carglumic acid in preparation of drugs for preventing and treating coronaviruses

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202010265448.1A CN111407754A (en) 2020-04-07 2020-04-07 Application of carglumic acid in preparing medicine for preventing and treating coronavirus

Publications (1)

Publication Number Publication Date
CN111407754A true CN111407754A (en) 2020-07-14

Family

ID=71485493

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202010265448.1A Pending CN111407754A (en) 2020-04-07 2020-04-07 Application of carglumic acid in preparing medicine for preventing and treating coronavirus

Country Status (2)

Country Link
CN (1) CN111407754A (en)
WO (1) WO2021203703A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021203703A1 (en) * 2020-04-07 2021-10-14 中国科学院深圳先进技术研究院 Use of carglumic acid in preparation of drugs for preventing and treating coronaviruses
WO2022015198A1 (en) * 2020-07-17 2022-01-20 Муса Тажудинович Абидов Vaccine and method of protection against coronavirus infection
WO2022088038A1 (en) * 2020-10-30 2022-05-05 中国科学院深圳先进技术研究院 Application of cay10603 in preparation of drugs for preventing and treating coronavirus-related diseases
WO2022088037A1 (en) * 2020-10-30 2022-05-05 中国科学院深圳先进技术研究院 Application of sirtinol in preparation of drug for preventing and treating coronavirus

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4389121A1 (en) * 2022-12-22 2024-06-26 Consejo Superior De Investigaciones Científicas (CSIC) Antiviral amino acid derivatives

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140170157A1 (en) * 2011-06-15 2014-06-19 Glaxosmithkline Intellectual Property (No.2) Limited Method of selecting therapeutic indications
CN105056246A (en) * 2015-08-18 2015-11-18 武汉武药科技有限公司 Carglumic acid solid composition and preparation method thereof
WO2017091777A1 (en) * 2015-11-24 2017-06-01 Vijay Krishnan Novel healthcare delivery, treatment, and payment model for specialty drugs

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10064826B2 (en) * 2013-03-15 2018-09-04 Navinta, Llc Direct compression and dry granulation processes for preparing carglumic acid tablets having less impurities than those produced by wet granulation process
EP3323410A1 (en) * 2016-11-22 2018-05-23 RECORDATI INDUSTRIA CHIMICA E FARMACEUTICA S.p.a. Pharmaceutical parenteral formulation containing carglumic acid
WO2018158249A1 (en) * 2017-02-28 2018-09-07 Dipharma S.A. Room temperature stable pharmaceutical composition comprising carglumic acid
CN111407754A (en) * 2020-04-07 2020-07-14 中国科学院深圳先进技术研究院 Application of carglumic acid in preparing medicine for preventing and treating coronavirus

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140170157A1 (en) * 2011-06-15 2014-06-19 Glaxosmithkline Intellectual Property (No.2) Limited Method of selecting therapeutic indications
CN105056246A (en) * 2015-08-18 2015-11-18 武汉武药科技有限公司 Carglumic acid solid composition and preparation method thereof
WO2017091777A1 (en) * 2015-11-24 2017-06-01 Vijay Krishnan Novel healthcare delivery, treatment, and payment model for specialty drugs

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
YADI ZHOU等: "Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2", 《CELL DISCOVERY》 *
孙超等: "加强新型冠状病毒肺炎患者肝损伤的临床研究", 《实用肝脏病杂志》 *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021203703A1 (en) * 2020-04-07 2021-10-14 中国科学院深圳先进技术研究院 Use of carglumic acid in preparation of drugs for preventing and treating coronaviruses
WO2022015198A1 (en) * 2020-07-17 2022-01-20 Муса Тажудинович Абидов Vaccine and method of protection against coronavirus infection
WO2022088038A1 (en) * 2020-10-30 2022-05-05 中国科学院深圳先进技术研究院 Application of cay10603 in preparation of drugs for preventing and treating coronavirus-related diseases
WO2022088037A1 (en) * 2020-10-30 2022-05-05 中国科学院深圳先进技术研究院 Application of sirtinol in preparation of drug for preventing and treating coronavirus

Also Published As

Publication number Publication date
WO2021203703A1 (en) 2021-10-14

Similar Documents

Publication Publication Date Title
CN111467363A (en) Application of sofosbuvir in preparation of medicine for preventing and treating coronavirus
CN111407754A (en) Application of carglumic acid in preparing medicine for preventing and treating coronavirus
CN111420024A (en) Application of bacitracin A in preparing medicine for preventing and treating coronavirus
CN111467338B (en) Application of pyroglutamic acid in preparation of medicine for preventing and treating novel coronavirus resistant to new coronary pneumonia
CN111467355B (en) Application of foscarnet sodium in preparing medicine for preventing and treating coronavirus
ES2970401T3 (en) Compounds and compositions for use in a method of treating parainfluenza virus
CN107281210A (en) Application of the azithromycin in anti infection of coronavirus
US20110098261A1 (en) Triterpenoid-based compounds useful as virus inhibitors
CN113967211A (en) Application of lycorine hydrochloride thioester in preparation of anti-coronavirus medicines
CN113069446A (en) Application of EL102 in preparation of medicine for treating diseases caused by novel coronavirus
CN108434167A (en) Application of the different corilagin in preparing anti-influenza virus medicament
CN112694463B (en) Application of isopentenyl chromone compound in preparation of anti-coronavirus medicines
KR101731607B1 (en) Composition for the prevention and treatment of antiviral comprising extracts of Epimedium koreanum
US20110105738A1 (en) Diaryl hepatonoid-based compounds useful as virus inhibitors
WO2022088037A1 (en) Application of sirtinol in preparation of drug for preventing and treating coronavirus
WO2022088047A1 (en) Application of itf2357 in preparation of drug for preventing and treating coronaviruses
WO2021253338A1 (en) Use of romidepsin in preventing and treating coronavirus-related diseases
CN113813366A (en) Application of romidepsin in preparation of medicine for preventing and treating novel anti-new-crown-pneumonia coronavirus
CN108420815B (en) Application of polyketone in inhibiting influenza virus
WO2022088025A1 (en) Application of panobinostat in preparing drug for prevention and treatment of coronavirus
WO2022088038A1 (en) Application of cay10603 in preparation of drugs for preventing and treating coronavirus-related diseases
CN116322681A (en) Antiviral use of liraglutide and gefitinib
CN111568900A (en) Application of indomethacin in resisting coronavirus infection
CN114432305A (en) Application of CAY10603 in preparing medicine for preventing and treating coronavirus
CN114432287A (en) Application of ITF2357 in preparation of medicine for preventing and treating coronavirus

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20200714